NasdaqCM:CPRXBiotechs
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In
Catalyst Pharmaceuticals (CPRX) has drawn investor attention after its rare-disease portfolio produced annual revenue of $596.958 million and net income of $221.323 million, putting the current share price of $31.42 into sharper focus.
See our latest analysis for Catalyst Pharmaceuticals.
Over the past year, Catalyst Pharmaceuticals has coupled solid reported profitability with strong momentum, with a 1-year total shareholder return of 43.54% and a 5-year total shareholder return of 442.66%...